OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...
Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes ...
Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...
Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.
Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...
In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...
Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...
On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...
A twice-yearly injection could significantly improve blood pressure control when taken as an add-on to existing treatments. | ...
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results